2. Search Result
Search Result
Results for "

vasodilatory activity

" in MedChemExpress (MCE) Product Catalog:

42

Inhibitors & Agonists

4

Peptides

1

Inhibitory Antibodies

8

Natural
Products

3

Isotope-Labeled Compounds

1

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-107632
    GYY4137
    Maximum Cited Publications
    8 Publications Verification

    		 Apoptosis STAT NF-κB NO Synthase COX TNF Receptor Interleukin Related Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity .
    GYY4137
  • HY-B0464
    Hydralazine hydrochloride
    3 Publications Verification

    		 PGE synthase NO Synthase Reactive Oxygen Species (ROS) DNA Methyltransferase COX Cardiovascular Disease Inflammation/Immunology Cancer
    Hydralazine hydrochloride is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine hydrochloride reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine hydrochloride inhibits NOS-2 (iNOS) and COX-2, and reduces the production of NO and PGEE2; meanwhile, Hydralazine hydrochloride scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine hydrochloride alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine hydrochloride directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine hydrochloride has been widely used in studies on hypertension, various cancers (such as cervical cancer, leukemia), spinal cord injury and the mechanisms of inflammatory pain .
    Hydralazine hydrochloride
  • HY-P0003
    Nesiritide

    Brain Natriuretic Peptide-32 human; BNP-32

    		 Natriuretic Peptide Receptor (NPR) Calcium Channel Cardiovascular Disease
    Nesiritide (Brain Natriuretic Peptide-32 human) is a recombinant human B-type natriuretic peptide. Nesiritide is a NPRs agonist, with Kd values of 7.3 and 13 pM for NPR-A and NPR-C, respectively. Nesiritide regulates V1/2 activation/inactivation of the L-type calcium channel. Nesiritide shows vasodilatory, diuretic, and natriuretic activities. Nesiritide is used in cardiovascular diseases such as heart failure and vascular remodeling after arterial injury .
    Nesiritide
  • HY-15556
    GSK269962A
    5+ Cited Publications

    GSK 269962

    		 ROCK Cardiovascular Disease Inflammation/Immunology
    GSK269962A (GSK 269962) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A has anti-inflammatory and vasodilatory activities .
    GSK269962A
  • HY-N2374
    Eupatorin
    2 Publications Verification

    		 Apoptosis NF-κB MMP Adrenergic Receptor Inflammation/Immunology Cancer
    Eupatorin is an orally active flavonoid with antiproliferative and vasodilatory properties. Eupatorin downregulates the expression levels of NF-κB, MMP9, IL-1β and TNF-α. Eupatorin induces apoptosis, G2/M phase cell cycle arrest, and reactive oxygen species (ROS) production. Eupatorin modulates the activities of muscarinic receptors and β-adrenergic receptors; inhibits sarcoplasmic reticulum calcium release and calcium channels; and activates the NO/sGC/cGMP pathway, indomethacin-sensitive pathway, and potassium channel pathway. Eupatorin exerts cytotoxic effects on cancer cell lines, and is metabolized by CYP1A1 and CYP1 family enzymes to form metabolites with antiproliferative activity. Eupatorin can be used in research related to breast cancer, hypertension, and leukemia .
    Eupatorin
  • HY-P990951
    Vixticibart

    REGN-5381

    		 Natriuretic Peptide Receptor (NPR) Cardiovascular Disease
    Vixticibart (REGN-5381) is a fully human IgG4 monoclonal antibody and NPR1 agonist that targets NPR1. Vixticibart stabilizes the receptor in an activated conformation by binding to the N-terminal domain of NPR1, and enhances the activity of endogenous ligands ANP and BNP without blocking ligand binding when these ligands are present. Vixticibart exerts vasodilatory and hypotensive effects by inducing cGMP production, preferentially dilating venous vessels to reduce systolic and venous pressure, but does not induce diuresis and may trigger a compensatory increase in heart rate. Vixticibart produces a synergistic hypotensive effect when combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and is currently mainly used in research related to heart failure and hypertension .
    Vixticibart
  • HY-B0464A
    Hydralazine
    3 Publications Verification

    		 DNA Methyltransferase Reactive Oxygen Species (ROS) COX NO Synthase PGE synthase Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    Hydralazine is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine inhibits NOS-2 (iNOS) and COX-2, and reduces the production of NO and PGEE2; meanwhile, Hydralazine scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine has been widely used in studies on hypertension, various cancers (such as cervical cancer, leukemia), spinal cord injury and the mechanisms of inflammatory pain .
    Hydralazine
  • HY-15556A
    GSK269962A hydrochloride
    5+ Cited Publications

    GSK 269962 hydrochloride

    		 ROCK Cardiovascular Disease Inflammation/Immunology
    GSK269962A hydrochloride (GSK 269962 hydrochloride) is a potent ROCK inhibitor with IC50s of 1.6 and 4 nM for recombinant human ROCK1 and ROCK2 respectively. GSK269962A hydrochloride has anti-inflammatory and vasodilatory activities .
    GSK269962A hydrochloride
  • HY-123068
    Captopril disulfide

    SQ 14551

    		 Drug Derivative Cardiovascular Disease
    Captopril disulfide (SQ 14551) is an orally active disulfide dimer prodrug. Captopril disulfide is metabolized to Captopril and acts as a Bradykinin potentiator. Captopril disulfide enhances the vasodilatory effect of Bradykinin in anesthetized rats and the contractile response of isolated guinea pig ileum to Bradykinin. Captopril disulfide exhibits antihypertensive activity in spontaneously hypertensive rats. Captopril disulfide can be used in hypertension-related research .
    Captopril disulfide
  • HY-107581
    MK-1903
    1 Publications Verification

    		 GPR109A MMP Metabolic Disease Inflammation/Immunology
    MK-1903 is an orally active full agonist of GPR109a/HCAR2, with an EC50 of 12.9 nM. MK-1903 activates antilipolytic and vasodilatory pathways, reduces plasma free fatty acid levels, and induces skin flushing. MK-1903 stimulates the expression of HCAR2 protein and regulates the inflammatory response of microglia. MK-1903 prevents the enhanced firing activity of spinal nociceptive neurons. MK-1903 triggers the release of MMP-9 and the formation of NET. MK-1903 can be used in the research of dyslipidemia and neuroinflammation-based central nervous system diseases .
    MK-1903
  • HY-122153
    VSN-16

    		Cannabinoid Receptor Cardiovascular Disease Inflammation/Immunology
    VSN-16 is a cannabinoid receptor agonist with vasodilatory activity. VSN-16 can be used for the study of multiple sclerosis .
    VSN-16
  • HY-121936
    Yohimbic acid

    		Adrenergic Receptor Drug Derivative Cardiovascular Disease Inflammation/Immunology Cancer
    Yohimbic acid is a derivative of Yohimbine Hydrochloride (HY-N0127). Yohimbic acid exhibits vasodilatory and anticancer activities. Yohimbic acid can be used for the research of cancer, inflammation and cardiovascular disease .
    Yohimbic acid
  • HY-B0464S1
    Hydralazine-d5 hydrochloride

    		Isotope-Labeled Compounds PGE synthase NO Synthase Reactive Oxygen Species (ROS) DNA Methyltransferase COX Cancer
    Hydralazine-d5 (hydrochloride) is deuterium-labeled Hydralazine (hydrochloride) (HY-B0464). Hydralazine hydrochloride is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine hydrochloride reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine hydrochloride inhibits NOS-2 (iNOS) and COX-2, and reduces the production of NO and PGEE2; meanwhile, Hydralazine hydrochloride scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine hydrochloride alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine hydrochloride directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine hydrochloride has been widely used in studies on hypertension, various cancers (such as cervical cancer, leukemia), spinal cord injury and the mechanisms of inflammatory pain .
    Hydralazine-d5 hydrochloride
  • HY-N4267
    Yangambin

    		Calcium Channel Platelet-activating Factor Receptor (PAFR) UGT Leukotriene Receptor TNF Receptor PGE synthase Interleukin Related Cardiovascular Disease Infection Inflammation/Immunology
    Yangambin is a PAF receptor antagonist and UGT1A1/UGT1A3 inhibitor, with an IC50 of 29.7 μM and a Ki of 17.1 μM against human UGT1A1, and an IC50 of 56.5 μM and a Ki of 66.8 μM against human UGT1A3. Yangambin blocks PAF-mediated responses, inhibits LTB4-mediated neutrophil infiltration, and suppresses inflammatory events and anaphylactic contraction. Yangambin acts as a central nervous system inhibitor to reduce spontaneous activity, and also exhibits analgesic, anticonvulsant, antileishmanial, vasodilatory and hypotensive effects. Yangambin blocks voltage-gated Ca 2+ channels, reduces the production of NO, TNF-α, IL-6 and PGE2 in cells, increases the production of IL-10, and exerts a protective effect against cardiovascular injury. Yangambin can be used in research related to allergies, cutaneous leishmaniasis, central nervous system diseases and cardiovascular diseases .
    Yangambin
  • HY-121936A
    Yohimbic acid hydrate

    		Adrenergic Receptor Drug Derivative Cardiovascular Disease Inflammation/Immunology Cancer
    Yohimbic acid hydrate is a derivative of Yohimbine Hydrochloride (HY-N0127). Yohimbic acid hydrate exhibits vasodilatory and anticancer activities. Yohimbic acid hydrate can be used for the research of cancer, inflammation and cardiovascular disease .
    Yohimbic acid hydrate
  • HY-B0203B
    (Rac)-Nebivolol

    (Rac)-R 065824

    		 Adrenergic Receptor NADPH Oxidase Cardiovascular Disease
    (Rac)-Nebivolol ((Rac)-R 065824) is a racemic isomer of Nebivolol. Nebivolol is a selective β1-adrenergic receptor antagonist with an IC50 value of 0.8 nM. Nebivolol can prevent up-regulation of Nox2/NADPH oxidase and lipoperoxidation in the early stages of ethanol-induced cardiac toxicity. Vasodilatory activity .
    (Rac)-Nebivolol
  • HY-122215
    Tilisolol hydrochloride

    N-696

    		 Adrenergic Receptor Endocrinology
    Tilisolol hydrochloride (N-696) is a non-selective β-adrenergic antagonist with vasodilatory and hypotensive activities. Tilisolol hydrochloride exerts its effects in canine coronary arteries by opening ATP-sensitive K+ channels. Tilisolol hydrochloride exhibits concentration-dependent relaxation in KCl-precontracted rat thoracic aorta. Tilisolol hydrochloride reduces diastolic blood pressure in a dose-dependent manner and slightly increases heart rate in spinal cord stimulated rats .
    Tilisolol hydrochloride
  • HY-B0464S
    Hydralazine-d4 hydrochloride

    		Isotope-Labeled Compounds PGE synthase NO Synthase Reactive Oxygen Species (ROS) DNA Methyltransferase COX Cardiovascular Disease
    Hydralazine-d4 hydrochloride is the deuterium labeled Hydralazine hydrochloride. Hydralazine hydrochloride is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine hydrochloride reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine hydrochloride inhibits NOS-2 (iNOS) and COX-2, and reduces the production of NO and PGEE2; meanwhile, Hydralazine hydrochloride scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine hydrochloride alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine hydrochloride directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine hydrochloride has been widely used in studies on hypertension, various cancers (such as cervical cancer, leukemia), spinal cord injury and the mechanisms of inflammatory pain .
    Hydralazine-d4 hydrochloride
  • HY-P3050
    Helospectin II

    		GCGR Cardiovascular Disease
    Helospectin II is a neuropeptide of the vasoactive intestinal peptide (VIP) family. Helospectin II has vasodilatory and antihypertensive activities, and decreases blood pressure. Helospectin II is originally isolated from the salivary gland venom of the lizard Heloderma suspectum .
    Helospectin II
  • HY-105749
    Pentamethonium bromide

    		Endogenous Metabolite Neurological Disease
    Pentamethonium bromide is a ganglion blocker that exhibits antihypertensive and vasodilatory activities .
    Pentamethonium bromide
  • HY-120941
    LASSBio-1359

    		Adenosine Receptor Cardiovascular Disease Inflammation/Immunology
    LASSBio-1359 is an adenosine A2A receptor agonist with vasodilatory and anti-inflammatory activities .
    LASSBio-1359
  • HY-N12843
    2-Deoxokanshone M

    Nardosinone acid

    		 Drug Metabolite Others
    2-Deoxokanshone M (Nardosinone acid) is a degradation product of Nardosinone (HY-N0380) and has potent vasodilatory activity .
    2-Deoxokanshone M
  • HY-119291
    RA642

    		Phosphodiesterase (PDE) Others
    RA642 is a compound with vasodilatory and hypertensive effects, with the activity of increasing arterial blood pressure, enhancing cerebral blood flow, reducing cerebrovascular resistance and peripheral resistance, and having a papaverine-like relaxant effect on smooth muscle in anesthetized animals.
    RA642
  • HY-P3053
    Helospectin I

    		GCGR Cardiovascular Disease
    Helospectin I is a neuropeptide of the vasoactive intestinal peptide (VIP) family. Helospectin I has vasodilatory and antihypertensive activities, and decreases blood pressure. Helospectin I is originally isolated from the salivary gland venom of the lizard Heloderma suspectum .
    Helospectin I
  • HY-121936R
    Yohimbic acid (Standard)

    		Reference Standards Adrenergic Receptor Cardiovascular Disease Inflammation/Immunology Cancer
    Yohimbic acid (Standard) is the analytical standard of Yohimbic acid (HY-121936). This product is intended for research and analytical applications. Yohimbic acid is a derivative of Yohimbine Hydrochloride (HY-N0127). Yohimbic acid exhibits vasodilatory and anticancer activities. Yohimbic acid can be used for the research of cancer, inflammation and cardiovascular disease .
    Yohimbic acid (Standard)
  • HY-107632G
    GYY4137

    		Apoptosis STAT NF-κB TNF Receptor NO Synthase Interleukin Related COX Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    GYY4137 (GMP) is the GMP-grade version of GYY4137 (HY-107632). Small molecules of GMP grade can be used as adjuvant reagents in cell therapy. GYY4137 (GMP) is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GYY4137 (GMP) can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocking the STAT3 pathway, demonstrating potent anticancer activity .
    GYY4137
  • HY-159484
    Hsp110/sGC-modulator-1

    		HSP Guanylate Cyclase Cardiovascular Disease
    Hsp110/sGC-modulator-1 (compound 17i), an orally active Hsp110/sGC dual-target regulator, exhibits optimal Hsp110 and sGC molecular activities as well as remarkable cell malignant phenotypes inhibitory and vasodilatory effects. Hsp110/sGC-modulator-1 (compound 17i) attenuates pulmonary vascular remodeling and right ventricular hypertrophy via Hsp110 suppression .
    Hsp110/sGC-modulator-1
  • HY-P0003A
    Nesiritide acetate

    Brain Natriuretic Peptide-32 human acetate; BNP-32 acetate

    		 Natriuretic Peptide Receptor (NPR) Calcium Channel Cardiovascular Disease
    Nesiritide (Brain Natriuretic Peptide-32 human) acetate is a recombinant human B-type natriuretic peptide. Nesiritide acetate is a NPRs agonist, with Kd values of 7.3 and 13 pM for NPR-A and NPR-C, respectively. Nesiritide acetate regulates V1/2 activation/inactivation of the L-type calcium channel. Nesiritide acetate shows vasodilatory, diuretic, and natriuretic activities. Nesiritide acetate is used in cardiovascular diseases such as heart failure and vascular remodeling after arterial injury .
    Nesiritide acetate
  • HY-134043
    Chlorthalidone Impurity G

    Chlorthalidone EP Impurity G

    		 Carbonic Anhydrase Cardiovascular Disease
    Chlorthalidone Impurity G (Chlorthalidone EP Impurity G) is a potential impurity found in commercial preparations of chlorthalidone with moderate antihypertensive effects. Chlorthalidone is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal tubule of the kidney, thereby preventing sodium and chloride reabsorption, resulting in decreased plasma volume and cardiac output. It also inhibits carbonic anhydrase (CA), including isoenzymes CAVB, VII, IX, XII, and XIII (Kis=2.8-23 nM) and to a lesser extent CAI, CAII, IV, VA, and VI (Ki=138-1,347 nM), mediating vasodilatory activity.
    Chlorthalidone Impurity G
  • HY-B0203BS2
    (Rac)-Nebivolol-d2,15N

    (Rac)-R 065824-d2,15N

    		 NADPH Oxidase Adrenergic Receptor Isotope-Labeled Compounds Cardiovascular Disease
    (Rac)-Nebivolol-d2, 15N is 15N and deuterated labeled (Rac)-Nebivolol (HY-B0203B). (Rac)-Nebivolol ((Rac)-R 065824) is a racemic isomer of Nebivolol. Nebivolol is a selective β1-adrenergic receptor antagonist with an IC50 value of 0.8 nM. Nebivolol can prevent up-regulation of Nox2/NADPH oxidase and lipoperoxidation in the early stages of ethanol-induced cardiac toxicity. Vasodilatory activity .
    (Rac)-Nebivolol-d2,15N
  • HY-B0464R
    Hydralazine hydrochloride (Standard)

    		Reference Standards PGE synthase NO Synthase Reactive Oxygen Species (ROS) DNA Methyltransferase COX Cardiovascular Disease Inflammation/Immunology Cancer
    Hydralazine (hydrochloride) (Standard) is the analytical standard of Hydralazine (hydrochloride). This product is intended for research and analytical applications. Hydralazine hydrochloride is an orally active, blood-brain barrier-permeable DNA methyltransferase inhibitor with vasodilatory, arterial smooth muscle relaxant and hypotensive activities. Hydralazine hydrochloride reactivates silenced tumor suppressor genes via mediating DNA demethylation, while exerting neuroprotective and anti-inflammatory properties. Hydralazine hydrochloride inhibits NOS-2 (iNOS) and COX-2, and reduces the production of NO and PGEE2; meanwhile, Hydralazine hydrochloride scavenges reactive oxygen species and inhibits macrophage activation. Hydralazine hydrochloride alleviates motor dysfunction, neuropathic inflammatory pain, and formalin-induced somatic and emotional pain responses. In addition, Hydralazine hydrochloride directly induces DNA strand breaks and sister chromatid exchange, exhibiting certain mutagenic characteristics. Hydralazine hydrochloride has been widely used in studies on hypertension, various cancers (such as cervical cancer, leukemia), spinal cord injury and the mechanisms of inflammatory pain .
    Hydralazine hydrochloride (Standard)
  • HY-W099339
    N-Ethylnicotinamide

    		Drug Intermediate Cardiovascular Disease
    N-Ethylnicotinamide is a compound with weak vasodilatory activity. N-Ethylnicotinamide also serves as the core scaffold of the antianginal agent Nicorandil (HY-B0341) and its derivatives .
    N-Ethylnicotinamide
  • HY-172817
    Prostaglandin A2 ethyl ester

    		Drug Derivative Cardiovascular Disease Inflammation/Immunology
    Prostaglandin A2 ethyl ester is an ethyl ester derivative of Prostaglandin A2 (HY-113041). Prostaglandin A2 ethyl ester exhibits vasodilatory activity and has a protective effect on the kidneys .
    Prostaglandin A2 ethyl ester
  • HY-N16748
    Heptazoline

    		Others Cardiovascular Disease
    Heptazoline is a carbazole alkaloid that can be isolated from the stem bark of Clausena excavata. Heptazoline exhibits significant antiplatelet aggregation activity (inhibiting platelet aggregation induced by arachidonic acid, collagen, etc.) and certain vasodilatory activity (inhibiting norepinephrine-induced contraction of rat aorta). Heptazoline can be used in antithrombotic research in the cardiovascular field .
    Heptazoline
  • HY-183907
    Cicletanine

    		Calcium Channel Cardiovascular Disease
    Cicletanine is a voltage-dependent Ca 2+ channel inhibitor. Cicletanine inhibits α-adrenoceptor-mediated Ca 2+ release pathway, and shows vasodilatory effects on isolated vascular smooth muscle. Cicletanine directly stimulates lysosomal and cytoplasmic cholesteryl ester hydrolase activity. Cicletanine can be used for the research of hypertension .
    Cicletanine
  • HY-180379
    Pelanserin

    		5-HT Receptor Adrenergic Receptor Cardiovascular Disease
    Pelanserin (Compound 1) is an orally active antihypertensive agent. Pelanserin is a potent 5-HT2 receptor antagonist. Pelanserin has the ability to block the activity of α-adrenergic receptor, with its ED50 being 0.03 μg/mL. Pelanserin has vasodilatory activity, with its ED100 being 5 μg. Pelanserin exhibits antihypertensive activity in hypertensive rats and renal hypertensive dog breeds. Pelanserin can be used for research on hypertension .
    Pelanserin
  • HY-N16779
    Angustine

    		Others Cardiovascular Disease Neurological Disease
    Angustine is a monoterpene indole alkaloid vasodilator. Angustine exhibits potent vasodilatory activity on isolated rat aorta at a concentration of 10 μM (vasodilation rate exceeding 90%). Angustine can be used in the study of diseases such as hypertension, cerebral vasospasm, and peripheral circulatory disorders. Angustine can be naturally extracted from the bark of Nauclea officinalis and is also present in plants of the genera Mitragyna, Uncaria, and Strychnos .
    Angustine
  • HY-107632R
    GYY4137 (Standard)

    		Reference Standards Apoptosis STAT NF-κB NO Synthase COX TNF Receptor Interleukin Related Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    GYY4137 (Standard) is the analytical standard of GYY4137 (HY-107632). This product is intended for research and analytical applications. GY4137 is a sustained-release H2S donor possessing vasodilatory, antihypertensive, and anti-inflammatory activities. GY4137 can inhibit cell growth, induce apoptosis, and cause cell cycle arrest by blocKing the STAT3 pathway, demonstrating potent anticancer activity .
    GYY4137 (Standard)
  • HY-182642
    MRS2339

    		P2X Receptor Nucleoside Antimetabolite/Analog Cardiovascular Disease
    MRS2339 is a ribose-modified nucleotide and a nucleotidase-resistant P2 receptor agonist. MRS2339 activates P2X4R. MRS2339 induces ionic currents via P2X receptors, reduces cardiomyocyte cross-sectional area and heart weight/body weight ratio, lacks vasodilatory activity, and extends the lifespan of mice with cardiomyopathy. MRS2339 can be used in research related to heart failure and cardiomyopathy .
    MRS2339
  • HY-106830
    Pelrinone

    		Phosphodiesterase (PDE) Cardiovascular Disease
    Pelrinone is an orally active cardiotonic agent and PDE III inhibitor with an IC50 of 36 μM. Pelrinone elevates intracellular cAMP levels. The action of Pelrinone is independent of β-adrenergic receptors, and it does not inhibit Na +/K +-ATPase. Pelrinone exerts positive inotropic and vasodilatory effects. Pelrinone inhibits platelet aggregation, reduces thrombus formation, and exerts weak anticoagulant activity without altering hematocrit or circulating platelet counts. Pelrinone can be used in research related to congestive heart failure and coronary thrombosis .
    Pelrinone
  • HY-183644
    LNO 9

    		Lysyl Oxidase Cardiovascular Disease
    LNO 9 is an orally active LOXL2 inhibitor and NO donor, with an IC50 of 0.17 μM against human LOXL2. LNO 9 competitively binds to the LTQ cofactor of LOXL2 to form an irreversible complex, thereby inhibiting collagen oxidation and abnormal cross-linking. LNO 9 releases nitric oxide (NO) to increase cGMP levels in pulmonary artery smooth muscle cells. LNO 9 inhibits hypoxia-induced collagen modification and possesses vasodilatory activity. LNO 9 ameliorates right ventricular hypertrophy and pulmonary artery medial thickness in rat models induced by hypoxia and Monocrotaline (HY-N0750), and can be used for research on pulmonary hypertension .
    LNO 9
  • HY-107581R
    MK-1903 (Standard)

    		Reference Standards GPR109A MMP Metabolic Disease Inflammation/Immunology
    MK-1903 (Standard) is the analytical standard of MK-1903 (HY-107581). This product is intended for research and analytical applications. MK-1903 is an orally active full agonist of GPR109a/HCAR2, with an EC50 of 12.9 nM. MK-1903 activates antilipolytic and vasodilatory pathways, reduces plasma free fatty acid levels, and induces skin flushing. MK-1903 stimulates the expression of HCAR2 protein and regulates the inflammatory response of microglia. MK-1903 prevents the enhanced firing activity of spinal nociceptive neurons. MK-1903 triggers the release of MMP-9 and the formation of NET. MK-1903 can be used in the research of dyslipidemia and neuroinflammation-based central nervous system diseases.
    MK-1903 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: